Enovis Schedules First Quarter 2022 Earnings Release and Conference Call
Enovis Corporation (NYSE: ENOV), an innovative medical technology company, announced it will release pro forma financial results for Q1 FY2022 on May 10, 2022. A public conference call will follow at 8:00 a.m. Eastern, where company officials will discuss the results. Interested parties can join the call by phone or through a webcast on Enovis’ website. The event aims to provide insights into the company's performance and strategies for growth.
- None.
- None.
Insights
Analyzing...
Wilmington, DE, April 14, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, today announced that it will issue a press release on the morning of Tuesday, May 10, 2022 providing pro forma financial results for the first quarter of fiscal year 2022.
The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 3684428 and through a webcast via Enovis’ website www.enovis.com under the “Investors” section. Access to a supplemental slide presentation will be found at the Enovis website under the same heading. A link to a replay of the call will also be available on the Enovis website later that day.
ABOUT ENOVIS™
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.
***
Derek Leckow
Vice President, Investor Relations
Enovis Corporation
+1-302-252-9129
investorrelations@enovis.com
Source: Enovis Corporation
